The endocannabinoid system is a signaling network in all mammals — comprising CB1 and CB2 receptors, endogenous cannabinoid molecules (anandamide, 2-AG), and synthesizing/degrading enzymes. It modulates appetite, pain, mood, immune function. Cannabis phytocannabinoids (THC, CBD) interact with this system.
The endocannabinoid system (ECS) is a signaling network present in all mammals — discovered through cannabis research in the early 1990s when scientists isolated the receptors that THC binds to. The ECS comprises cannabinoid receptors (CB1 and CB2), endogenous cannabinoid molecules (called endocannabinoids — chiefly anandamide and 2-AG), and the enzymes that synthesize and degrade those molecules. The ECS modulates appetite, pain perception, mood, immune function, memory, motor control, sleep, and many other physiological processes. Plant cannabinoids from cannabis (called phytocannabinoids — including THC and CBD) interact with the ECS to produce their effects. This guide describes the ECS at an educational level using language consistent with peer-reviewed research published via NIH and NLM.
The endocannabinoid system has two principal receptors. CB1 — primarily concentrated in the central nervous system (brain, spinal cord). CB1 is the receptor most directly responsible for the psychoactive effect of THC. CB2 — primarily concentrated in the peripheral tissues, immune system, and gastrointestinal tract. CB2 is the receptor more closely associated with anti-inflammatory and immune-modulating effects. Both receptors are G protein-coupled receptors that modulate cellular signaling when activated.
The body produces its own cannabinoid-like molecules called endocannabinoids. The two principal endocannabinoids are anandamide (AEA — named from the Sanskrit 'ananda' meaning bliss) and 2-arachidonoylglycerol (2-AG). These molecules are synthesized on-demand when receptors are stimulated, signal through CB1 and CB2, and are then degraded by enzymes (FAAH degrades anandamide; MAGL degrades 2-AG). This on-demand synthesis-and-degradation cycle distinguishes the ECS from many other neurotransmitter systems.
Research literature associates the ECS with regulation of many physiological processes:
“The endocannabinoid system is a complex cell-signaling system involved in regulating a range of functions and processes, including sleep, mood, appetite, memory, reproduction and fertility.”
THC is a partial agonist at CB1 — meaning it binds and activates the receptor. The high affinity at CB1 produces the characteristic intoxicating effect of cannabis. THC also has activity at CB2. CBD interacts with the ECS differently: it binds weakly to CB1 (does not produce intoxication), modulates CB2 activity, and has additional activity at non-cannabinoid receptors (serotonin 5-HT1A, TRPV1, PPAR, others). Both phytocannabinoids essentially 'mimic' or modulate the activity of the body's endogenous cannabinoids at receptor sites.
The endocannabinoid system was discovered through cannabis research. In 1988, researchers identified the CB1 receptor as the binding site for THC. The CB2 receptor was identified in 1993. The endogenous cannabinoid molecules (anandamide, 2-AG) were discovered subsequently — but the system was named retroactively because cannabis research led the way. Many other species — including mammals, birds, fish, and even some invertebrates — have functional endocannabinoid systems.
Endocannabinoid system research is active but limited by federal Schedule I status of cannabis (21 USC § 812) — which has historically restricted research access in the United States. Findings on therapeutic applications of cannabinoids beyond FDA-approved indications (Epidiolex for specific seizures, Marinol/dronabinol for chemotherapy-induced nausea) remain emerging. Consumers should avoid making clinical claims based on ECS research and consult licensed healthcare providers for medical questions.